Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Cirrhosis

Free Subscription Articles published in J Gastroenterol Hepatol Retrieve available abstracts of 126 articles: HTML format

Single Articles

November 2026
1. MELA LP, Spirakou S, Mela M
   Aspirin in "Compensated" Cirrhosis: Does the Evidence Concern First or Recurrent Decompensation?
   J Gastroenterol Hepatol. 2026 Nov 4. doi: 10.1111/jgh.70867.
   PubMed    
   
   
   
2. JEON SH, Heo NY, Maeng SA, Yoo HW, et al
   A Novel Anchoring Catheter Improves the Success, Efficiency, and Satisfaction of Paracentesis in Refractory Ascites: A Multicenter Randomized Crossover Trial.
   J Gastroenterol Hepatol. 2026;41:3529-3538.
   PubMed     Abstract available
   
   
   October 2026
3. ZHANG DS, Tsutsumi T, Muthiah MD
   MASH Cirrhosis: A Stage-Specific Framework for Care and Clinical Trial Design.
   J Gastroenterol Hepatol. 2026 Oct 30. doi: 10.1111/jgh.70860.
   PubMed     Abstract available
   
   
   
4. ABBARH S, Sawaf B, Cerqueira TL, Huttner HB, et al
   Association of Aspirin With Improved Clinical Outcomes and Survival in Patients With Compensated Cirrhosis: A Propensity Score-Matched Study of 25 782 Individuals.
   J Gastroenterol Hepatol. 2026 Oct 1. doi: 10.1111/jgh.70780.
   PubMed     Abstract available
   
   
   September 2026
5. WU C, Gao J, Gao B, Wang K, et al
   Demethylzeylasteral Targets the Sp1/AGAP2 Axis to Impair Autophagic Flux and Induce Apoptosis in Hepatic Stellate Cells.
   J Gastroenterol Hepatol. 2026 Sep 27. doi: 10.1111/jgh.70778.
   PubMed     Abstract available
   
   
   
6. LEE A, Han CI, Yang K, Yang H, et al
   Emerging Indices Outperform Traditional Fibrosis Scores in Young Metabolic Dysfunction-Associated Steatotic Liver Disease Across Divergent Screening Goals.
   J Gastroenterol Hepatol. 2026;41:2925-2937.
   PubMed     Abstract available
   
   
   
7. GAO F, Zhang Y, Ding Y, Li Y, et al
   Noninvasive Detection of MASH and Fibrotic Burden Using Ultrasound-Derived LIID and LSM in MASLD: A Multicenter Study.
   J Gastroenterol Hepatol. 2026;41:2843-2852.
   PubMed     Abstract available
   
   
   
8. SOGABE M, Okahisa T, Kagawa M, Shinomiya R, et al
   Comparing the Effect of Changes in Alcohol Intake on Liver Fibrosis Risk Scores Among Patients With Two Distinct Types of Steatotic Liver Disease.
   J Gastroenterol Hepatol. 2026;41:2697-2708.
   PubMed     Abstract available
   
   
   August 2026
9. STRASSER SI, Thompson AJ, Gupta R, Lubel J, et al
   Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective.
   J Gastroenterol Hepatol. 2026 Aug 9. doi: 10.1111/jgh.70616.
   PubMed     Abstract available
   
   
   
10. GILANI SAZ, Naseer M
    Post-ERCP Outcomes in Cirrhotics Patients With Thrombocytopenia: A Propensity-Matched Retrospective Comparative Analysis.
    J Gastroenterol Hepatol. 2026 Aug 6. doi: 10.1111/jgh.70638.
    PubMed    
    
    
    July 2026
11. HE C, Wei Y, Zheng K, Wang X, et al
    Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial.
    J Gastroenterol Hepatol. 2026 Jul 7. doi: 10.1111/jgh.70554.
    PubMed     Abstract available
    
    
    April 2026
12. GAO A, Luo J, Ye X, Hu Y, et al
    Comments on "Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort".
    J Gastroenterol Hepatol. 2026 Apr 17. doi: 10.1111/jgh.70395.
    PubMed    
    
    
    
13. WANG ZV, Boumelhem BB, Pennell T, Bachovchin WW, et al
    A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:1311-1322.
    PubMed     Abstract available
    
    
    March 2026
14. JINATO T, Sikaroodia M, Gilleveta PM, Dissayabutra T, et al
    Gut Microbiome Signatures Differ in Cirrhosis With and Without Hepatocellular Carcinoma in a Southeast Asian Cohort.
    J Gastroenterol Hepatol. 2026 Mar 30. doi: 10.1111/jgh.70358.
    PubMed     Abstract available
    
    
    
15. KIM MN
    Reply Letter to: A Critical Assessment of "Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis".
    J Gastroenterol Hepatol. 2026 Mar 25. doi: 10.1111/jgh.70335.
    PubMed    
    
    
    
16. MIN EK, Kim SS, Ahn B, Kim DG, et al
    Diagnostic Value of MR Elastography and MRI-Proton Density Fat Fraction in Cirrhosis Based on Explant Liver Histology.
    J Gastroenterol Hepatol. 2026 Mar 13. doi: 10.1111/jgh.70316.
    PubMed     Abstract available
    
    
    
17. MUJAHID MUF, Haider E
    A Critical Assessment of "Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis".
    J Gastroenterol Hepatol. 2026 Mar 7. doi: 10.1111/jgh.70328.
    PubMed    
    
    
    
18. HSIEH ML, Su TH, Lin YC, Chen YY, et al
    Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:1041-1051.
    PubMed     Abstract available
    
    
    
19. LI Y, Li J, Dullaart RPF, Moshage H, et al
    Bacterial Extracellular Vesicles in the Pathogenesis and Treatment of Liver Diseases.
    J Gastroenterol Hepatol. 2026;41:880-894.
    PubMed     Abstract available
    
    
    February 2026
20. O'HARA SP, Bogert PT, Dickinson S, Chen X, et al
    Plasma Biomarkers of Senescence in Cholestatic Liver Disease: A Signature of Risk Stratification and Progression.
    J Gastroenterol Hepatol. 2026 Feb 13. doi: 10.1111/jgh.70279.
    PubMed     Abstract available
    
    
    
21. JANG TY
    Interaction Between Genetic Variants and Air Pollution and the Risk of Hepatocellular Carcinoma in Cirrhotic Patients.
    J Gastroenterol Hepatol. 2026 Feb 6. doi: 10.1111/jgh.70282.
    PubMed    
    
    
    
22. DENG X, Huang N, Du K, Zhang H, et al
    The Spleen Promotes Liver Sinusoidal Endothelial Cell Angiogenesis by Stimulating the TGFbeta/Smad2/3 Pathway Through GDF15.
    J Gastroenterol Hepatol. 2026;41:774-786.
    PubMed     Abstract available
    
    
    January 2026
23. XU J, Ma H, Yang W, Tu R, et al
    ATF3 Mediates the Immunoregulatory Role of the Tim-3 Pathway in Primary Biliary Cholangitis.
    J Gastroenterol Hepatol. 2026 Jan 15. doi: 10.1111/jgh.70234.
    PubMed     Abstract available
    
    
    
24. MAK LY, Lai JC, Liu K, Lui R, et al
    Chronic Hepatitis B Infection: Patient Guidance.
    J Gastroenterol Hepatol. 2026;41:61-77.
    PubMed     Abstract available
    
    
    
25. LIM AH, Litwin PS, Dionela W, Tse E, et al
    Endoscopic Ultrasound Guided Portal Pressure Gradient Measurement in Predicting Outcomes of Abdominal Surgery in Patients With Chronic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:286-292.
    PubMed     Abstract available
    
    
    
26. HUANG YC, Wang CW, Huang JC, Liang PC, et al
    FIB-4 Serves as a Referral Index for Coronary Artery Calcification in Patients With MASLD.
    J Gastroenterol Hepatol. 2026;41:332-340.
    PubMed     Abstract available
    
    
    December 2025
27. LIU Z, Jiang H, Li F, Xie R, et al
    Bile Acid Metabolites Control Th17/Treg Balance in Primary Biliary Cholangitis: Mechanisms of Disease Progression and Therapeutic Targets.
    J Gastroenterol Hepatol. 2025 Dec 7. doi: 10.1111/jgh.70189.
    PubMed     Abstract available
    
    
    
28. SATO S, Kawai H, Yamaguchi M, Nago H, et al
    Fibrosis in Asymptomatic Steatotic Liver Disease With Normal Alanine Aminotransferase: Analysis of 2448 Health Check-Up Cohort by Ultrasound Attenuation Imaging and Shear Wave Elastography.
    J Gastroenterol Hepatol. 2025;40:2987-2996.
    PubMed     Abstract available
    
    
    
29. YU H, Wu J, Li M, Hu C, et al
    Diagnostic and Prognostic Performance of the Agile 3+ Score in Patients With Chronic Hepatitis B and Concurrent MASLD After Complete Viral Suppression With Nucleos(t)ide Analogues.
    J Gastroenterol Hepatol. 2025;40:2963-2975.
    PubMed     Abstract available
    
    
    November 2025
30. CHEN YC, Chang YP, Lee JY, Chen CY, et al
    Predictive Value of Serum Mac-2 Binding Protein Glycosylation Isomer for Hepatic Fibrosis in Hepatitis C Virus-Infected Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2025 Nov 14. doi: 10.1111/jgh.70160.
    PubMed     Abstract available
    
    
    October 2025
31. FAN C, He X, Zhou Y, Ye C, et al
    The Effects of CD100 Stimulation on Primary Human Hepatocytes (PHHs) and Its Implications in HBV-Related Liver Cirrhosis.
    J Gastroenterol Hepatol. 2025 Oct 21. doi: 10.1111/jgh.70123.
    PubMed     Abstract available
    
    
    
32. AGARWAL A, Pachisia AV, Agarwal S, Mehta S, et al
    Celiac Disease and Its Impact on Liver-Related Outcomes in Patients With All-Cause Cirrhosis: The CELIHEP Study.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70082.
    PubMed     Abstract available
    
    
    
33. XU L, Liu J
    Comment on Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70114.
    PubMed    
    
    
    
34. KIM MN, Park GU, You SC, Lee JS, et al
    Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV-Related Cirrhosis: A Landmark Analysis.
    J Gastroenterol Hepatol. 2025 Oct 1. doi: 10.1111/jgh.70078.
    PubMed     Abstract available
    
    
    
35. SHI H, Dou D, Zhang F, Du Y, et al
    Prevalence and Bidirectional Association Between Autoimmune Liver Disease and Inflammatory Bowel Disease: A Meta-Analysis.
    J Gastroenterol Hepatol. 2025;40:2362-2372.
    PubMed     Abstract available
    
    
    
36. ZENG X, Li Z, Chen Y, Yao H, et al
    Impairing Islets in Newborn Mice Promotes Liver Fibrosis and Carcinoma Development in a Rapid NASH Model.
    J Gastroenterol Hepatol. 2025;40:2601-2612.
    PubMed     Abstract available
    
    
    September 2025
37. ABREU ES, Fernandes GP, Lacerda HC, Reginato PH, et al
    Efficacy and Safety of Obeticholic Acid as Second-Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
    J Gastroenterol Hepatol. 2025 Sep 30. doi: 10.1111/jgh.70094.
    PubMed     Abstract available
    
    
    August 2025
38. HEGAZY RA
    Unraveling Liver Cirrhosis: Bridging Pathophysiology to Innovative Therapeutics.
    J Gastroenterol Hepatol. 2025 Aug 3. doi: 10.1111/jgh.70037.
    PubMed     Abstract available
    
    
    July 2025
39. CHEN Y, Zhai D, Shen J, Hu W, et al
    Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
    J Gastroenterol Hepatol. 2025 Jul 26. doi: 10.1111/jgh.70003.
    PubMed     Abstract available
    
    
    
40. JANG TY, Wang CW, Liang PC, Wei YJ, et al
    Steatotic Liver Disease-Related Polygenetic Risk Score Prediction of Hepatocellular Carcinoma in Nucleotide/Nucleoside Analog-Treated Chronic Hepatitis B.
    J Gastroenterol Hepatol. 2025 Jul 24. doi: 10.1111/jgh.70021.
    PubMed     Abstract available
    
    
    June 2025
41. CAINES A, Lu M, Wu T, Trudeau S, et al
    Pre-Diagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis.
    J Gastroenterol Hepatol. 2025 Jun 23. doi: 10.1111/jgh.17035.
    PubMed     Abstract available
    
    
    
42. WANG L, Zhao Y, Duan B, Wang Y, et al
    Iron Quantification Using Spectral CT-Based Material Decomposition Technique for Noninvasive Hepatic Fibrosis Staging: An Experimental Study.
    J Gastroenterol Hepatol. 2025 Jun 4. doi: 10.1111/jgh.17031.
    PubMed     Abstract available
    
    
    
43. XIA Y, Tie J, Wang G, Wu H, et al
    Benefits of TIPS for Patients With Large Ascites Preceding Recurrent or Refractory ascites: A Multicenter Cohort Study.
    J Gastroenterol Hepatol. 2025;40:1574-1585.
    PubMed     Abstract available
    
    
    May 2025
44. MATSUBARA Y, Tsuboi A, Shigenobu S, Hirata I, et al
    Clinical Significance of Small-Bowel Mucosal Changes in Liver Cirrhosis Patients With Suspected Small-Bowel Bleeding: A Capsule Endoscopy Study.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.17002.
    PubMed     Abstract available
    
    
    
45. JOSHI A, Raja HAA, Roy P, Latif F, et al
    Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta-Analysis.
    J Gastroenterol Hepatol. 2025 May 19. doi: 10.1111/jgh.16999.
    PubMed     Abstract available
    
    
    April 2025
46. TAMAKI N, Huang DQ, Lee HW, Park SY, et al
    Head-to-Head Comparison of Long-Term HCC Risk of Antivirals-Treated Versus Untreated Low-Level Viremia in HBV-Compensated Cirrhosis.
    J Gastroenterol Hepatol. 2025 Apr 27. doi: 10.1111/jgh.16986.
    PubMed     Abstract available
    
    
    
47. OGAWA E, Kawano A, Kohjima M, Koyanagi T, et al
    Long-Term Liver Morbidity and Mortality After Hepatitis C Virus Elimination by Direct-Acting Antivirals.
    J Gastroenterol Hepatol. 2025;40:971-978.
    PubMed     Abstract available
    
    
    March 2025
48. 
    Correction to 'Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance'.
    J Gastroenterol Hepatol. 2025 Mar 14. doi: 10.1111/jgh.16918.
    PubMed    
    
    
    
49. JAFARI-KHORCHANI M, Pantopoulos K, Zare-Mehrjardi MJ, Allameh A, et al
    Sequential Changes in NOX4 Expression, Oxidative Stress Indices, PIIINP, and Liver Histopathology During Hepatocellular Carcinogenesis Induced in Mice.
    J Gastroenterol Hepatol. 2025 Mar 3. doi: 10.1111/jgh.16914.
    PubMed     Abstract available
    
    
    
50. JIANG H, Yu H, Huang Y, Li M, et al
    Natural History and Prognosis of Chronic Hepatitis B Patients in the Indeterminate Phase.
    J Gastroenterol Hepatol. 2025;40:720-730.
    PubMed     Abstract available
    
    
    
51. JAYABALAN D, Huang Y, Calzadilla-Bertot L, Adams LA, et al
    Natural History and Predictors of Clinical Outcomes in Autoimmune Liver Diseases: A Multicenter Study.
    J Gastroenterol Hepatol. 2025;40:731-740.
    PubMed     Abstract available
    
    
    February 2025
52. GIRI S, Ingawale S, Khatana G, Gore P, et al
    Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia-Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021.
    J Gastroenterol Hepatol. 2025 Feb 27. doi: 10.1111/jgh.16922.
    PubMed     Abstract available
    
    
    
53. NAKAKUKI N, Maekawa S, Takano S, Osawa L, et al
    TCR Repertoire Analysis During Therapeutic Interventions in Liver Diseases Using Next-Generation Sequencing.
    J Gastroenterol Hepatol. 2025;40:537-547.
    PubMed     Abstract available
    
    
    January 2025
54. PENG J, Zhang L, Dong Y, Long W, et al
    Factors Influencing Liver Cirrhosis Progression in Wilson's Disease Patients: A Retrospective Cohort Study Over 5 Years.
    J Gastroenterol Hepatol. 2025 Jan 31. doi: 10.1111/jgh.16889.
    PubMed     Abstract available
    
    
    
55. VAZ K, Kemp W, Majeed A, Lubel J, et al
    Validation of serum non-invasive tests of liver fibrosis as prognostic markers of clinical outcomes in people with fatty liver disease in Australia.
    J Gastroenterol Hepatol. 2025;40:241-249.
    PubMed     Abstract available
    
    
    December 2024
56. MALANDRIS K, Arampidis D, Mainou M, Papadopoulos N, et al
    FibroScan-AST score for diagnosing fibrotic MASH: A systematic review and meta-analysis of diagnostic test accuracy studies.
    J Gastroenterol Hepatol. 2024;39:2582-2591.
    PubMed     Abstract available
    
    
    
57. PAN L, Wang L, Ma H, Ding F, et al
    Relevance of combined influence of nutritional and inflammatory status on non-alcoholic fatty liver disease and advanced fibrosis: A mediation analysis of lipid biomarkers.
    J Gastroenterol Hepatol. 2024;39:2853-2862.
    PubMed     Abstract available
    
    
    
58. KIM K, Lee Y, Lee JS, Kim MN, et al
    Incidence of metabolic dysfunction-associated steatotic liver disease and advanced fibrosis and impact of overweight/obesity in elderly population: a nationwide cohort study.
    J Gastroenterol Hepatol. 2024;39:2845-2852.
    PubMed     Abstract available
    
    
    
59. CHANG ML, Le PH, Chen WT, Chen TD, et al
    Distinct characteristics of various autoimmune liver diseases: A 22-year hospital-based study in Taiwan.
    J Gastroenterol Hepatol. 2024;39:2835-2844.
    PubMed     Abstract available
    
    
    
60. MAK LY, Hui RW, Chung MSH, Wong DK, et al
    Regression of liver fibrosis after HBsAg loss: A prospective matched case-control evaluation using transient elastography and serum enhanced liver fibrosis test.
    J Gastroenterol Hepatol. 2024;39:2826-2834.
    PubMed     Abstract available
    
    
    November 2024
61. JAROENLAPNOPPARAT A, Prasitsumrit V, Ponvilawan B, Waitayangkoon P, et al
    Clostridioides difficile infection increases in-hospital mortality, length of stay, and hospital cost but not 30-day mortality in cirrhotic patients.
    J Gastroenterol Hepatol. 2024 Nov 13. doi: 10.1111/jgh.16807.
    PubMed     Abstract available
    
    
    
62. ZENG X, Liao Y, Cheng W
    Transient receptor potential channel 6 knockout ameliorates hepatic fibrosis by inhibiting the activation and proliferation of hepatic stellate cells.
    J Gastroenterol Hepatol. 2024 Nov 7. doi: 10.1111/jgh.16802.
    PubMed     Abstract available
    
    
    
63. CHANG YP, Liu CH, Huang CB, Lee JY, et al
    Serum Mac-2 binding protein glycosylation isomer dynamics in patients achieving sustained virologic response for hepatitis C virus.
    J Gastroenterol Hepatol. 2024;39:2439-2446.
    PubMed     Abstract available
    
    
    
64. WONGTRAKUL W, Niltwat S, Charatcharoenwitthaya N, Karaketklang K, et al
    Global prevalence of advanced fibrosis in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024;39:2299-2307.
    PubMed     Abstract available
    
    
    October 2024
65. PRINCE DS, Hoque S, Kim C, Maher S, et al
    Cirrhosis in primary practice: many patients remain potentially undiagnosed and are not receiving liver cancer surveillance.
    J Gastroenterol Hepatol. 2024 Oct 24. doi: 10.1111/jgh.16782.
    PubMed     Abstract available
    
    
    
66. LI Y, Chen L, Li S, Song H, et al
    The m6A reader IGF2BP1 contributes to the activation of hepatic stellate cells through facilitating TUBB4B mRNA stabilization.
    J Gastroenterol Hepatol. 2024 Oct 15. doi: 10.1111/jgh.16765.
    PubMed     Abstract available
    
    
    
67. LEOW YW, Chan WL, Lai LL, Mustapha NRN, et al
    LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver disease.
    J Gastroenterol Hepatol. 2024;39:2182-2189.
    PubMed     Abstract available
    
    
    
68. YU H, Huang Y, Li M, Jiang H, et al
    Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease.
    J Gastroenterol Hepatol. 2024;39:2169-2181.
    PubMed     Abstract available
    
    
    
69. YANG J, Choi WM, Lee D, Shim JH, et al
    Revisiting the steatosis-associated fibrosis estimator score in young Asian subjects with steatotic liver disease and consideration for population variability.
    J Gastroenterol Hepatol. 2024;39:2112-2119.
    PubMed     Abstract available
    
    
    
70. ALATAS FS, Yamaza T, Matsuura T, Ongko L, et al
    Potential role of stem cells from human exfoliated deciduous teeth in inducing liver regeneration.
    J Gastroenterol Hepatol. 2024;39:2190-2196.
    PubMed     Abstract available
    
    
    September 2024
71. PASSOS PRC, Filho VOC, Noronha MM, Hyppolito EB, et al
    Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Sep 25. doi: 10.1111/jgh.16752.
    PubMed     Abstract available
    
    
    August 2024
72. BANERJEE A, Blinston D, Narain MA
    Inhibition of liver fibrosis by TET1 may be B cell mediated: Supporting evidence from a case of TNFAIP3 deficiency.
    J Gastroenterol Hepatol. 2024;39:1706-1707.
    PubMed    
    
    
    July 2024
73. MALANDRIS K, Papandreou S, Vasilakou D, Kakotrichi P, et al
    Efficacy of pharmacologic interventions on magnetic resonance imaging biomarkers in patients with nonalcoholic fatty liver disease: systematic review and network meta-analysis.
    J Gastroenterol Hepatol. 2024;39:1219-1229.
    PubMed     Abstract available
    
    
    June 2024
74. MALIK S, Tenorio BG, Moond V, Dahiya DS, et al
    Systematic review of machine learning models in predicting the risk of bleed/grade of esophageal varices in patients with liver cirrhosis: A comprehensive methodological analysis.
    J Gastroenterol Hepatol. 2024 Jun 17. doi: 10.1111/jgh.16645.
    PubMed     Abstract available
    
    
    
75. WURSTLE S, Schneider T, Karapetyan S, Hapfelmeier A, et al
    LINAS-Score: prognostic model for mortality assessment in patients with cirrhotic liver and infected ascites.
    J Gastroenterol Hepatol. 2024 Jun 5. doi: 10.1111/jgh.16637.
    PubMed     Abstract available
    
    
    
76. LEE JS, Lee HW, Kim MN, Kim BK, et al
    Hepatitis C virus infection in patients undergoing surgery in a single tertiary academic center.
    J Gastroenterol Hepatol. 2024;39:1155-1163.
    PubMed     Abstract available
    
    
    May 2024
77. HAYASHI M, Abe K, Sugaya T, Takahata Y, et al
    A low baseline serum myostatin concentration is associated with poor clinical outcome in patients with primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 May 30. doi: 10.1111/jgh.16639.
    PubMed     Abstract available
    
    
    
78. SUN Z, Guo Y, Xu X, Zhou C, et al
    Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway.
    J Gastroenterol Hepatol. 2024 May 28. doi: 10.1111/jgh.16635.
    PubMed     Abstract available
    
    
    
79. LIM J, Kim JH, Kim SE, Han SK, et al
    Validation of MELD 3.0 in patients with alcoholic liver cirrhosis using prospective KACLiF cohort.
    J Gastroenterol Hepatol. 2024 May 8. doi: 10.1111/jgh.16591.
    PubMed     Abstract available
    
    
    
80. ENDO K, Kakisaka K, Abe T, Yusa K, et al
    Positive impact of obesity on the prognosis of liver cirrhosis.
    J Gastroenterol Hepatol. 2024 May 3. doi: 10.1111/jgh.16590.
    PubMed     Abstract available
    
    
    
81. LEE S, Choi J, Park JH, Lim CY, et al
    Dynamic liver volume change in predicting hepatic decompensation and long-term effects of stereotactic body radiation therapy.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16588.
    PubMed     Abstract available
    
    
    
82. MAKRI ES, Evripidou K, Polyzos SA
    Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2024;39:806-817.
    PubMed     Abstract available
    
    
    April 2024
83. LIU Y, Hu Y, Li B, Su R, et al
    Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.
    J Gastroenterol Hepatol. 2024 Apr 12. doi: 10.1111/jgh.16547.
    PubMed     Abstract available
    
    
    March 2024
84. WANG X, Liu H, Wang Y, Wang P, et al
    Novel protein C6ORF120 promotes liver fibrosis by activating hepatic stellate cells through the PI3K/Akt/mTOR pathway.
    J Gastroenterol Hepatol. 2024 Mar 24. doi: 10.1111/jgh.16538.
    PubMed     Abstract available
    
    
    February 2024
85. 
    Correction to "Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis".
    J Gastroenterol Hepatol. 2024 Feb 25. doi: 10.1111/jgh.16529.
    PubMed    
    
    
    
86. WANG J, Zhang Y, Ma Y, Zhao S, et al
    TET1 inhibits liver fibrosis by blocking hepatic stellate cell activation.
    J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16443.
    PubMed     Abstract available
    
    
    January 2024
87. AMJAD W, Jiang Z, Lai M
    Statin use in cirrhosis and its association with incidence of portal vein thrombosis.
    J Gastroenterol Hepatol. 2024 Jan 25. doi: 10.1111/jgh.16495.
    PubMed     Abstract available
    
    
    
88. ZHU J, Xia Y, Liu X, Zhang C, et al
    Preventing variceal rebleeding in cirrhotic patients with portal vein thrombosis: A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16489.
    PubMed     Abstract available
    
    
    
89. NIE MT, Wang PQ, Shi PM, Hong XL, et al
    Rifaximin treatment shapes a unique metagenome-metabolism network in patients with decompensated cirrhosis.
    J Gastroenterol Hepatol. 2024 Jan 17. doi: 10.1111/jgh.16484.
    PubMed     Abstract available
    
    
    December 2023
90. GOPAL P, Banerjee D, Karad A, Dandi K, et al
    Gastrointestinal: Congenital portosystemic shunt (Abernathy type 2) with cirrhosis of liver.
    J Gastroenterol Hepatol. 2023 Dec 26. doi: 10.1111/jgh.16456.
    PubMed    
    
    
    November 2023
91. SHI L, Feng G, Yang X, Zhang Y, et al
    Potential of PAQosome as a therapeutic target for hepatic fibrosis.
    J Gastroenterol Hepatol. 2023 Nov 28. doi: 10.1111/jgh.16427.
    PubMed     Abstract available
    
    
    
92. ALLAIRE M, Thabut D
    The applicability of Baveno criteria in the setting of hepatocellular carcinoma remains a controversy.
    J Gastroenterol Hepatol. 2023 Nov 21. doi: 10.1111/jgh.16415.
    PubMed    
    
    
    October 2023
93. OH JH, Saeed WK, Kim HY, Lee SM, et al
    Hepatic stellate cells activate and avoid death under necroptosis stimuli: Hepatic fibrosis during necroptosis.
    J Gastroenterol Hepatol. 2023 Oct 9. doi: 10.1111/jgh.16368.
    PubMed     Abstract available
    
    
    
94. GIRI S, Singh A, Kolhe K, Kale A, et al
    Reply: Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
    J Gastroenterol Hepatol. 2023 Oct 7. doi: 10.1111/jgh.16378.
    PubMed    
    
    
    
95. ITO T, Morooka H, Takahashi H, Fujii H, et al
    Identification of clinical phenotypes associated with poor prognosis in patients with nonalcoholic fatty liver disease via unsupervised machine learning.
    J Gastroenterol Hepatol. 2023;38:1832-1839.
    PubMed     Abstract available
    
    
    
96. SHAHRANI S, Gill SS, Sooi CY, Skantha R, et al
    Frequency of significant steatosis and compensated advanced chronic liver disease among adults with chronic liver disease.
    J Gastroenterol Hepatol. 2023;38:1818-1822.
    PubMed     Abstract available
    
    
    September 2023
97. KANG SH, Kim MY, Han SK, Baik SK, et al
    Subclinical diabetes confirmed by 75-g OGTT influence on the prognosis of decompensated cirrhosis.
    J Gastroenterol Hepatol. 2023 Sep 11. doi: 10.1111/jgh.16327.
    PubMed     Abstract available
    
    
    
98. GASPAR R, Silva M, Cardoso P, Goncalves R, et al
    Spleen stiffness: a new tool to predict high-risk varices in cirrhotic patients.
    J Gastroenterol Hepatol. 2023 Sep 1. doi: 10.1111/jgh.16344.
    PubMed     Abstract available
    
    
    August 2023
99. JIANG H, Xu N, Zhang W, Wei H, et al
    Do gut microbiome-targeted therapies improve liver function in cirrhotic patients? A systematic review and meta-analysis.
    J Gastroenterol Hepatol. 2023 Aug 15. doi: 10.1111/jgh.16329.
    PubMed     Abstract available
    
    
    
100. ANIRVAN P
     Portal vein thrombosis in cirrhosis: exploring the uncharted waters.
     J Gastroenterol Hepatol. 2023 Aug 12. doi: 10.1111/jgh.16328.
     PubMed    
     
     
     
101. LI R, Liu J, Han P, Shi R, et al
     Associations between abdominal obesity indices and pathological features of non-alcoholic fatty liver disease: Chinese visceral adiposity index.
     J Gastroenterol Hepatol. 2023;38:1316-1324.
     PubMed     Abstract available
     
     
     
102. CHETWOOD JD, Sabih AH, Chan K, Salimi S, et al
     Epidemiology, characteristics, and outcomes of patients with acute-on-chronic liver failure in Australia.
     J Gastroenterol Hepatol. 2023;38:1325-1332.
     PubMed     Abstract available
     
     
     July 2023
103. CHO MS, Lee SK, Kwon JH, Nam SW, et al
     Hepatobiliary and Pancreatic: Challenges in the diagnosis of hepatic nodules in patients with alcoholic liver cirrhosis.
     J Gastroenterol Hepatol. 2023 Jul 10. doi: 10.1111/jgh.16277.
     PubMed    
     
     
     
104. CHOI WM, Yoo SY, Chang JI, Han S, et al
     A model for predicting poor survival in patients with cirrhosis undergoing portosystemic shunt embolization.
     J Gastroenterol Hepatol. 2023 Jul 7. doi: 10.1111/jgh.16280.
     PubMed     Abstract available
     
     
     
105. PODDAR U, Samanta A, Sarma MS, Kumar B, et al
     How to suspect the presence of high-risk esophageal varices and when to start endoscopic surveillance in children with biliary atresia?
     J Gastroenterol Hepatol. 2023 Jul 5. doi: 10.1111/jgh.16267.
     PubMed     Abstract available
     
     
     
106. LIU M, Qiu H, Zhang W, Mei T, et al
     Evaluation of blood-based PRO-C3 testing as a diagnostic marker for staging liver fibrosis: A systematic review and meta-analysis.
     J Gastroenterol Hepatol. 2023;38:1018-1027.
     PubMed     Abstract available
     
     
     
107. SHEN J, Cao J, Chen M, Zhang Y, et al
     Recent advances in the role of exosomes in liver fibrosis.
     J Gastroenterol Hepatol. 2023;38:1083-1088.
     PubMed     Abstract available
     
     
     
108. SEDAROUS M, Youssef M, Adekunle AD, Babajide O, et al
     A nationwide study of liver disease hospitalizations during the coronavirus pandemic in the United States.
     J Gastroenterol Hepatol. 2023;38:1148-1157.
     PubMed     Abstract available
     
     
     
109. JIANG N, Xiao Y, Yuan K, Wang Z, et al
     Effect of intestinal microbiota on liver disease and its related future prospection: From the perspective of intestinal barrier damage and microbial metabolites.
     J Gastroenterol Hepatol. 2023;38:1056-1071.
     PubMed     Abstract available
     
     
     June 2023
110. MINORETTI P, Emanuele E
     Reversing nonalcoholic fatty liver disease-related cirrhosis by inhibiting pyruvate kinase M2: a role for shikonin?
     J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16273.
     PubMed    
     
     
     
111. SHARMA BC, Maharshi S, Sachdeva S, Mahajan B, et al
     Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double-blind randomized controlled trial.
     J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16266.
     PubMed     Abstract available
     
     
     
112. GIRI S, Singh A, Kolhe K, Kale A, et al
     Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis.
     J Gastroenterol Hepatol. 2023 Jun 24. doi: 10.1111/jgh.16263.
     PubMed     Abstract available
     
     
     
113. ISHIBA H, Sumida Y, Kamada Y, Fujii H, et al
     Noninvasive tests predict liver-related events and mortality in patients with nonalcoholic fatty liver disease: sub-analysis of the CLIONE-Asia study.
     J Gastroenterol Hepatol. 2023;38:896-904.
     PubMed     Abstract available
     
     
     May 2023
114. DONG Y, Liu Y, Liu X, Ma H, et al
     Multi-omics profiling of primary hepatic stellate cells from advanced liver fibrosis patients reveals distinctive molecular signatures.
     J Gastroenterol Hepatol. 2023 May 24. doi: 10.1111/jgh.16221.
     PubMed     Abstract available
     
     
     
115. WU CW, Wong GL, Wong VW, Yam TF, et al
     Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages.
     J Gastroenterol Hepatol. 2023 May 22. doi: 10.1111/jgh.16218.
     PubMed     Abstract available
     
     
     
116. KIM DS, Kim BK, Lee JS, Lee HW, et al
     Noninvasive risk assessment of hepatic decompensation in patients with hepatitis B virus-related liver cirrhosis.
     J Gastroenterol Hepatol. 2023 May 15. doi: 10.1111/jgh.16210.
     PubMed     Abstract available
     
     
     
117. TIWARI A, Mehrotra M, Hasan A, Agarwal J, et al
     Hepatitis B virus liver decompensation: antiviral therapy for all.
     J Gastroenterol Hepatol. 2023;38:833-834.
     PubMed    
     
     
     
118. AHMED Z, Badal J, Nawras M, Battepati D, et al
     Role of rifaximin in the management of alcohol-associated hepatitis: A systematic review and meta-analysis.
     J Gastroenterol Hepatol. 2023;38:703-709.
     PubMed     Abstract available
     
     
     April 2023
119. VERMA N, Vojjala N, Mishra S, Valsan A, et al
     Machine learning can guide suitability of consultation and patient referral through telemedicine for hepatobiliary diseases.
     J Gastroenterol Hepatol. 2023 Apr 28. doi: 10.1111/jgh.16194.
     PubMed     Abstract available
     
     
     March 2023
120. MNATZAGANIAN G, MacLachlan JH, Allard N, Brown C, et al
     Missed opportunities for diagnosis of hepatitis B and C in individuals diagnosed with decompensated cirrhosis or hepatocellular carcinoma.
     J Gastroenterol Hepatol. 2023 Mar 3. doi: 10.1111/jgh.16162.
     PubMed     Abstract available
     
     
     
121. WONG GL
     Editorial: Appraising liver fibrosis with eagle eyes.
     J Gastroenterol Hepatol. 2023;38:343.
     PubMed    
     
     
     
122. ZHAO Q, Liang L, Zhai F, Ling G, et al
     A bibliometric and visualized analysis of liver fibrosis from 2002 to 2022.
     J Gastroenterol Hepatol. 2023;38:359-369.
     PubMed     Abstract available
     
     
     February 2023
123. ZHAO X, Shi X, Gu H, Zhou W, et al
     Association between handgrip strength, nonalcoholic fatty liver disease, advanced hepatic fibrosis and its modifiers: evidence from the NHANES database of the US.
     J Gastroenterol Hepatol. 2023 Feb 18. doi: 10.1111/jgh.16150.
     PubMed     Abstract available
     
     
     January 2023
124. CHO SH, Song TJ, Park JS, Yoon JH, et al
     Comparison of the long-term outcomes between proximal and distal IgG4-related sclerosing cholangitis: a multicenter cohort study.
     J Gastroenterol Hepatol. 2023 Jan 29. doi: 10.1111/jgh.16136.
     PubMed     Abstract available
     
     
     
125. BHATEJA A, Bodh V, Chauhan A
     Role of Nutrition in the management of hepatic encephalopathy - Do we know all?
     J Gastroenterol Hepatol. 2023 Jan 21. doi: 10.1111/jgh.16131.
     PubMed     Abstract available
     
     
     
126. ZHANG Q, Jia R, Chen M, Wang J, et al
     Antagonizing EZH2 combined with vitamin D3 exerts a synergistic role in anti-fibrosis through bidirectional effects on hepatocytes and HSCs.
     J Gastroenterol Hepatol. 2023 Jan 18. doi: 10.1111/jgh.16126.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum